Key result
Adding antiplatelet therapy to OAC fails to reduce ischemic stroke while increasing major bleeding.
Why the study?
Patients with AF and concomitant atherosclerotic vascular disease require oral anticoagulation for stroke prevention, while adding antiplatelet therapy for atherothrombotic prevention may increase intracranial and major bleeding. Recent randomized trials have expanded the evidence base beyond stable coronary disease, motivating an updated stroke-focused synthesis.
Does adding single antiplatelet therapy to oral anticoagulation reduce ischemic stroke without increasing intracranial hemorrhage or major bleeding compared to oral anticoagulation alone in patients with atrial fibrillation and concomitant atherosclerotic vascular disease?
Meta-Analysis (n=6,240)
Does adding single antiplatelet therapy to oral anticoagulation reduce ischemic stroke without increasing intracranial hemorrhage or major bleeding compared to oral anticoagulation alone in patients with atrial fibrillation and concomitant atherosclerotic vascular disease?
In patients with atrial fibrillation and established atherosclerotic vascular disease (>1 year post-ACS/PCI), oral anticoagulant monotherapy is preferred over combination therapy with an antiplatelet agent because adding antiplatelet therapy fails to reduce ischemic stroke while significantly increasing intracranial hemorrhage, major bleeding, and cardiovascular mortality.
Answers are grounded in this paper and cite their sources.
Combination therapy does not reduce ischemic stroke; challenges addition of antiplatelet agents to anticoagulation in AF with atherosclerosis.
Introduction/Purpose: Patients with atrial fibrillation (AF) and concomitant atherosclerotic vascular disease present a common therapeutic dilemma: oral anticoagulation is required for cardioembolic stroke prevention, while antiplatelet therapy may appear attractive for prevention of atherothrombotic events. However, combined therapy may increase intracranial and major bleeding. Recent randomized trials, including ATIS-NVAF in patients with recent ischemic stroke and coexisting atherosclerotic disease, have expanded the evidence base beyond stable coronary disease. We performed an updated stroke-focused meta-analysis comparing oral anticoagulation alone versus anticoagulation plus single antiplatelet therapy. Materials/Methods: PubMed, Embase, Cochrane CENTRAL, ClinicalTrials.gov, and reference lists were searched for randomized controlled trials enrolling adults requiring long-term oral anticoagulation with concomitant coronary, cerebrovascular, or peripheral atherosclerotic disease. Trials restricted to the first year after acute coronary syndrome or percutaneous coronary intervention were excluded. Primary outcomes were ischemic stroke, intracranial hemorrhage (ICH), and ISTH-defined major bleeding. Risk ratios (RRs) with 95% confidence intervals (CIs) were pooled using Mantel-Haenszel random-effects models with restricted maximum likelihood estimation. Heterogeneity was assessed using I². Leave-one-out sensitivity analyses was performed. Results: Seven randomized trials enrolling 6,240 patients were included. Combination therapy did not reduce ischemic stroke compared with anticoagulation alone (RR 0.91, 95% CI 0.60-1.36; p=0.63; I²=0%). In contrast, combination therapy increased ICH by 64% (RR 1.64, 95% CI 1.03-2.61; p=0.037; I²=0%) and approximately doubled ISTH major bleeding (RR 2.03, 95% CI 1.47-2.79; p<0.0001; I²=39%). Myocardial infarction, any stroke, systemic embolism, and all-cause mortality did not differ significantly between strategies. Cardiovascular mortality was higher with combination therapy (RR 1.39, 95% CI 1.04-1.86; p=0.025). Leave-one-out analyses showed no significant ischemic stroke benefit in any iteration, while the direction of ICH and major-bleeding harm remained stable. Conclusion: In patients with AF and established atherosclerotic vascular disease, adding single antiplatelet therapy to oral anticoagulation did not reduce ischemic stroke but significantly increased intracranial hemorrhage and major bleeding. These findings support anticoagulant monotherapy as the preferred long-term antithrombotic strategy when no separate time-limited indication for antiplatelet therapy exists.
No takes yet. Share an insight, caveat, or question.
Singh et al. (2026) conducted a meta-analysis in Atrial fibrillation and concomitant atherosclerotic vascular disease (n=6,240). Oral anticoagulation plus single antiplatelet therapy vs. Oral anticoagulation alone was evaluated on Ischemic stroke (RR 0.91, 95% CI 0.60-1.36, p=0.63). Adding single antiplatelet therapy to oral anticoagulation did not reduce ischemic stroke but increased ICH and major bleeding.
Synapse has enriched 10 related papers. Consider them for comparative context: